| Similar Articles |
|---|
 |
The Motley Fool
September 10, 2010
Brian D. Pacampara |
A Potential Blockbuster Roars Ahead Johnson & Johnson made a good choice to purchase Cougar Biotechnology.   |
The Motley Fool
October 11, 2010
Brian Orelli |
A Dendreon Killer? Not Yet. Johnson & Johnson's abiraterone looks good, but won't knock off the newcomer. |
The Motley Fool
May 2, 2011
Brian Orelli |
Prostate Cancer Drug Roars Ahead Johnson & Johnson's buy of Cougar paid off, but look in the rear view mirror. |
The Motley Fool
June 18, 2010
Brian Orelli |
Double the Approvals! Double the Fun! These twins will take it. sanofi-aventis and Novartis both received FDA approvals for their cancer drugs yesterday. |
The Motley Fool
May 3, 2011
Brian Orelli |
Brakes Are Off at Dendreon Ramping up sales, one month at a time. |
The Motley Fool
May 10, 2005
Charly Travers |
Dendreon in the Spotlight The small biotech's prostate cancer drug is in phase 3 development. Is this company worth investing in? |
The Motley Fool
April 30, 2010
Brian Orelli |
Pricey Provenge Pumps Up Dendreon Dendreon's prostate cancer drug is approved, but at what cost, and will insurance pay for it? |
The Motley Fool
May 16, 2007
Brian Lawler |
GPC's Next Cancer Drug? GPC Biotech prepares for its future as it awaits an FDA decision on its lead drug. Investors, take note. |
The Motley Fool
February 7, 2011
Brian Orelli |
Zibotentan Stopped, Long Live Provenge (for Now) Dendreon is looking good although it's not out of the woods yet. |
The Motley Fool
September 14, 2009
Brian Orelli |
More Tests for Drug for Cancer Patients The Vanilla trial might not have come up positive, but at least sanofi-aventis and Regeneron Pharmaceuticals will keep trying to show that aflibercept is capable of helping cancer patients live longer. |
The Motley Fool
May 4, 2009
Robert Steyer |
Beyond Provenge -- The Next Hot Cancer Drug? The search for prostate cancer treatments is filled with prospects and littered with failures. Which companies have the best chance of success? |
The Motley Fool
December 16, 2011
Brian Orelli |
Dendreon 2011: Supply Constrained to Missed Guidance A year in review for the biotech. |
The Motley Fool
December 14, 2010
Brian Orelli |
An Ounce of Prevention, a Pound of Blockbuster Sales Amgen's Xgeva recently gained Food and Drug Administration approval to treat cancer patients that have bone metastasis. |
The Motley Fool
May 10, 2006
Brian Lawler |
Dendreon Drives On Will the FDA say yes to a new cancer drug? Investors, take note. |
The Motley Fool
December 27, 2011
Brian Orelli |
Exelixis 2011: Not What the Doctor Ordered A tale of an inability to get a Special Protocol Assessment from the FDA. |
The Motley Fool
June 23, 2009
Brian Orelli |
Wonder Drug! Maybe? Get the facts before jumping on this one. |
The Motley Fool
September 1, 2010
Brian Orelli |
Dendreon: One Step Closer to Worry-Free Back in July, the Centers for Medicare & Medicaid Services announced that it planned on reviewing the reimbursement for Dendreon's prostate cancer treatment Provenge. |
The Motley Fool
November 10, 2006
Brian Lawler |
Dendreon Pending Approval A lot is riding on what the FDA will say about the small pharma's drug for prostate cancer. Investors, take note. |
The Motley Fool
June 1, 2010
Brian Orelli |
Save Your Money, Dendreon As much as doctors would like to prescribe Dendreon's Provenge for their patients, manufacturing limitations will keep demand outpacing supply for awhile. |
The Motley Fool
March 8, 2010
Brian Orelli |
Really? A 59% Share Price Jump for That? Justified or not, InterMune skyrockets ahead of an FDA panel meeting. |
The Motley Fool
March 2, 2011
Brian Orelli |
When Will Dendreon Make Money? Not for awhile ... it's a biotech thing. |
The Motley Fool
October 29, 2007
Brian Lawler |
World's Scariest Stock: Dendreon Investing in the biotech sector is scary enough for most investors. Dendreon's scary future should makes this stock an under-performer. |
The Motley Fool
May 18, 2011
Brian Orelli |
More Data, Same Controversy Will Amgen's Xgeva be used to delay bone metastasis? |
The Motley Fool
July 23, 2007
Brian Lawler |
GPC's Date With the FDA A document released by the FDA outlines its concerns with GPC's lead drug. Investors, take note. |
The Motley Fool
June 4, 2007
Brian Orelli |
OXiGENE's Moving Ahead The drug maker reaches a deal with FDA on its lead compound. Investors, take note. |
The Motley Fool
November 3, 2011
David Williamson |
Medivation Investors: Why Your Stock Just Jumped 140% Medivation shares pop on trial success for prostate cancer treatment MDV3100. |
The Motley Fool
May 31, 2011
Brian Orelli |
Profit From This Growing Drug Trend Cancer drugs press on. |
The Motley Fool
January 31, 2008
Brian Lawler |
Prioritizing Millennium The FDA grants a speedy review for Millennium Pharmaceuticals's lead multiple myeloma drug. |
The Motley Fool
May 28, 2010
Brian Orelli |
This Drug Doesn't Work. But All Is Not Lost. Novartis cancer drug fails one trial, but there's still hope. |
The Motley Fool
December 20, 2004
Charly Travers |
More Trouble at Big Pharma AstraZeneca's lung cancer drug is not as effective as once hoped. |
The Motley Fool
February 26, 2008
Brian Orelli |
The Less-Flashy Prostate Cancer Treatment GTx shows off clinical trial data for a drug that counters the side effects of prostate cancer treatments. |
The Motley Fool
February 16, 2010
Brian Orelli |
For Blockbuster Cancer Drugs, Approvals Are the Easy Part Don't get too excited. As an investor, you can lower your risk by investing in cancer drug companies after a clinical trial success but before an FDA approval, but you'll also reduce your reward. |
The Motley Fool
September 29, 2010
Brian Orelli |
Better Buy: Spectrum Pharmaceuticals or Dendreon? A battle of the sales-ramping drugmakers. |
The Motley Fool
September 25, 2009
Brian Orelli |
Dendreon Struts Its Stuff Like a peacock without any FDA-approved feathers. |
The Motley Fool
September 26, 2006
Brian Lawler |
GPC's Trial Glee A new platinum-based cancer treatment yields encouraging results. Investors, take note. |
The Motley Fool
November 21, 2008
Brian Orelli |
The Comeback of the Century? AstraZeneca is trying to revive Iressa. |
The Motley Fool
November 19, 2004
Charly Travers |
A New Drug for Lung Cancer Genentech and OSI's launch of Tarceva brings a new choice in the treatment of lung cancer. |
The Motley Fool
July 31, 2007
Brian Orelli |
GPC Takes a Pit Stop The biotech company pulls its New Drug Application for Satraplatin. There is something twisted about having to wait to get a drug to market because it's performing better than expected. Investors, take note. |
The Motley Fool
January 12, 2004
Dave Marino-Nachison |
All Eyes on Dendreon The cancer fighter's shares rocketed today on good news out of Phase III trials. |
BusinessWeek
June 21, 2004
Catherine Arnst |
Cancer Superdrugs, Costly Side Effects New therapies are extending lives, but the prices could weigh down the nation. Oncologists, pharmaceutical companies, and the government will have to focus on the best way to lower prices for these drugs. |
The Motley Fool
November 16, 2010
Luke Timmerman |
Dendreon Prepares to Take Some Heat Over Cancer Drug Prices Dendreon looking for off-label uses for its prostate cancer drug. |
The Motley Fool
June 6, 2011
Luke Timmerman |
Exelixis Zeroes In on Lead Drug, Sees Activity in the Bones of Prostate Cancer Patients Is Exelixis' risky bet about to pay off? |
The Motley Fool
April 14, 2009
Brian Orelli |
Sell Dendreon! No, Buy Dendreon! Dendreon, everyone's favorite tiny biotech, just got bigger because of positive phase 3 results for its prostate cancer treatment, Provenge. |
The Motley Fool
March 16, 2010
Brian Orelli |
How to Lose $114 Million in One Day You've got to be a very trusting investor to buy shares in pharmaceutical company, MannKind. |
The Motley Fool
April 27, 2011
Brian Orelli |
Falling Into the Zaltrap Lung cancer out, colon cancer in phase 3 clinical trial for Regeneron Pharmaceuticals' new drug. |
BusinessWeek
October 6, 2003
Gene G. Marcial |
Dendreon: New Weapons against Tumors What's so hot about Dendreon, which leaped from 3 last year to 9.25 on Sept. 24? The little-known biotech develops immunologically based cancer remedies, and its lead product, Provenge, is aimed at prostate cancer. |
The Motley Fool
November 1, 2011
Brian Orelli |
Not Such an Excellent Outcome With the FDA Exelixis gets knocked down for not getting an SPA. |
The Motley Fool
February 15, 2008
Brian Lawler |
Dendreon's Not-So-New Data Development-stage drugmaker Dendreon releases "new data" on lead cancer drug Provenge; unfortunately, the data wasn't the data that investors are waiting for. |
The Motley Fool
April 4, 2008
Brian Lawler |
A Few Thoughts on Dendreon Let's talk about the upcoming Dendreon study results. |
The Motley Fool
July 16, 2009
Brian Orelli |
Keep Your Chin Up, J&J An FDA advisory committee smacked down its drug candidate. |
